StockData
Invivyd, Inc. logo

Invivyd, Inc. (IVVD) stock

IVVDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3052% below fair value
$0.47−0.04 (-8.21%)

Close on Nov 18, 2026Market cap $138.68MP/E –Yield –

Invivyd revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Invivyd's revenue for the twelve months ending Jun 30, 2026 was $58.37M, up 26.3% year over year. For fiscal 2025 it was $53.43M, up 110.5% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$53.43M+110.5%
FY2024Dec 31, 2024$25.38M–
FY2023Dec 31, 2023$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$14.29M+21.2%
Q1 FY2026Mar 31, 2026$13.74M+21.6%
Q4 FY2025Dec 31, 2025$17.21M+24.5%
Q3 FY2025Sep 30, 2025$13.13M+41.2%
Q2 FY2025Jun 30, 2025$11.79M+420.6%
Q1 FY2025Mar 31, 2025$11.30M–
Q4 FY2024Dec 31, 2024$13.82M–
Q3 FY2024Sep 30, 2024$9.30M–
Q2 FY2024Jun 30, 2024$2.26M–
Q1 FY2024Mar 31, 2024$0–
Q4 FY2023Dec 31, 2023$0–
Q3 FY2023Sep 30, 2023$0–
Q2 FY2023Jun 30, 2023$0–

More Invivyd figures

See a number that looks wrong?